OnKure Therapeutics updates on PIKture-01 trial progress, financial results, and expansion of PI3Ka programs, with milestones expected through 2026. OnKure Therapeutics provided an update on its ...

Relay Therapeutics specializes in developing targeted therapies for cancer patients, with a particular emphasis on precision medicines. The company’s flagship product, RLY-2608, is a PI3Ka inhibitor ...

Bank of New York Mellon Corp raised its position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) by 18.0% in the fourth quarter, according to the company in its most recent ...

"I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next quarter ...

PIKture-01 trial update including additional PK data, mature single agent and initial combination data expected in the second half of 2025; reported encouraging preliminary data in December 2024 - ...

“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next ...

“I am extremely pleased with the progress we made last year. With three PI3Ka inhibitor programs, including one in clinical development and a second development candidate expected next ...